NCT06123026PHASE4RecruitingAccepts Healthy Volunteers

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

Northwestern University

Start Date

12/18/2023

Completion Date

6/30/2024

Summary

The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.

Eligibility Criteria

Age Range: 18 years to 50 years

Inclusion Criteria: * pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises * ages 18 to 50 * con provide informed consent in English Exclusion Criteria: * Age under 18 or above 50 * gestational ages before 16 weeks 0 days or after 20 weeks 0 days * unable to provide written consent in English * hypertensive disorder * uncontrolled hypertension or known hypersensitivity to ergot derivatives * History of cardiac valvular disorders * history of pulmonary fibrosis * documented bipolar schizophrenia * documented allergy to medication, including lactose intolerance (placebo pill involves lactose)

Interventions

DRUG

Cabergoline

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Lactation SuppressedSecond Trimester Abortion

Locations

Northwestern Medical Center

Chicago, Illinois 60611

United States